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Abstract: Acute respiratory distress syndrome is the primary cause of death in patients with coron-
avirus disease 2019 (COVID-19) pneumonia. Our study aims to determine the association between
serum markers and mortality in COVID-19 patients with respiratory failure. This retrospective
study was conducted in a tertiary care hospital in South Korea. Forty-nine patients with COVID-19,
who required high flow nasal cannulation or mechanical ventilation from February 2020 to April
2021, were included. Demographic and laboratory data were analyzed at baseline and on Day 7
of admission. We found that serum creatinine, troponin, procalcitonin, and soluble interleukin-2
receptor (sIL-2R) at baseline were more elevated in the non-survivor group, but were not associated
with mechanical ventilator use on Day 7. Older age, PaO2/FiO2 ratio, lymphocyte and platelet counts,
lactate dehydrogenase, IL-6, C-reactive protein, and sIL-2R on Day 7 were significantly associated
with mortality. Delta sIL-2R (Day 7–Day 0) per standard deviation was significantly higher in the
non-survivor group (adjusted hazard ratio 3.225, 95% confidence interval (CI) 1.151–9.037, p = 0.026).
Therefore, sIL-2R could predict mortality in COVID-19 patients with respiratory failure. Its sustained
elevation suggests a hyper-inflammatory state, and mirrors the severity of COVID-19 in patients
with respiratory failure, thereby warranting further attention.
Keywords: coronavirus disease 2019; soluble interleukin-2 receptor; respiratory failure; mortality
1. Introduction
In December 2019, an outbreak of severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) infection occurred in Wuhan, China. The major cause of death in patients
with coronavirus disease 2019 (COVID-19) pneumonia was determined to be multi-organ
failure, including respiratory failure, which is a severe disease often requiring invasive
ventilation [1,2]. For COVID-19 acute respiratory distress syndrome (ARDS), mortality can
range between 26% and 61.5% if the patient is admitted to a critical care setting at any time,
and 65.7% in patients who receive mechanical ventilation [2].
Previous studies have discovered risk factors associated with poor prognosis in pa-
tients with COVID-19, namely, older age [3], D-dimer [3], and procalcitonin [4]. Among
the various inflammatory cytokine and chemokine levels assessed in several studies, tu-
mor necrosis factor alpha (TNF-α), interferon-γ-induced protein 10 (IP-10), monocyte
chemoattractant protein 1 (MCP-1), chemokine (C-C motif), ligand 3 (CCL-3), and distinct
interleukins (IL) (IL-2, IL-6, IL-7, IL-10) have been shown to be significantly associated
with disease severity, and in particular, elevated in patients admitted to intensive care units
(ICUs) [5]. New cytometric parameters, such as Monocyte Distribution Width (MDW) and
Neutrophil-to-Lymphocyte Ratio (NLR), were recently found to correlate well with the
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clinical severity of COVID-19-associated inflammatory disorder [6,7]. Notably, the serum
levels of some interleukins have the potential to discriminate between mild and severe
disease, and can possibly be used as prognostic markers [5].
The circulating soluble IL2 receptor (sIL-2R) has been shown to regulate T-lymphocyte
activation in various immunological disorders, and increased sIL-2R concentration in
plasma predicts a decreased cellular response to IL-2 [8].
The host immune response of COVID-19 suggests an immune signature consisting
of elevated serum cytokines (IL-6 and TNF-α); elevated inflammatory serum markers
including ferritin, lactate dehydrogenase (LDH), D-dimer, C-reactive protein (CRP), and
coagulation factors; impaired interferon responses; and peripheral lymphopenia [3,9,10].
In this study, among the several inflammatory markers tested in clinical practice,
sIL-2R and IL-6 were investigated for an association with mortality in COVID-19 patients
with severe respiratory failure.
2. Materials and Methods
2.1. Patient Recruitment
Patient data were retrospectively collected from the ICU of a tertiary hospital in
South Korea, from February 2020 to April 2021. We reviewed the medical records of
patients who were confirmed to be COVID-19-positive by the detection of viral RNA in
their nasopharyngeal secretions or sputum by a real-time reverse transcriptase polymerase
chain reaction test. Patients who were diagnosed with respiratory failure and received
high flow nasal cannula (HFNC) oxygen therapy or mechanical ventilation were included.
Respiratory failure was defined as a PaO2/FiO2 ratio (the ratio of partial pressure of oxygen
in the arterial blood, PaO2, to the fraction of inspired oxygen, FiO2), of less than 300.
All patients confirmed to be COVID-19-positive were treated as per the treatment pro-
tocol released by the Society of Critical Care Medicine [11]. Patients underwent laboratory
tests including CRP, procalcitonin, IL-6, and sIL-2R at the time of admission (Day 0), and
on the seventh day of hospitalization (Day 7). The level of sIL-2R was measured using
an automated immune chemiluminescent assay with the IMMULITE® 2000 XPi system
(Siemens Healthcare GmbH, Erlangen, Germany). To measure the severity of disease, we
calculated the Acute Physiology And Chronic Health Evaluation II (APACHE II) score at
the time of admission, and a sequential organ failure assessment (SOFA) score at the time
of admission and on Day 7.
2.2. Data Collection
All data were collected from electronic medical records of patients. The following
clinical and laboratory data on Day 0 and Day 7 were collected: age; sex; comorbidities;
prognosis; P/F ratio; baseline serum markers including CRP, procalcitonin, IL-6, and sIL-2R;
SOFA score; and APACHE II score.
2.3. Statistical Analysis
Continuous variables are reported as median with interquartile ranges (IQR, 25th
to 75th percentiles), while categorical variables are reported as numbers (percentage).
Categorical variables were compared using the chi-square test and continuous variables
using either the independent t-test or Mann–Whitney U test, according to the non-normal
distribution of data.
Bivariate correlations were made by two-tailed Pearson correlation tests and survival
curves were shown using Kaplan–Meier analysis. We further investigated the relation-
ship between clinical parameters and mortality using Cox proportional hazard models,
with stepwise selection of variables that were found to be significant on univariate regres-
sion analysis. In all cases, p values < 0.05 were considered statistically significant. All
statistical analyses were performed using IBM SPSS Statistics version 25.0 (IBM Corp.,
Armonk, NY, USA).
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2.4. Ethics
This research protocol was approved by the Institutional Review Board of Severance
Hospital, South Korea (IRB No. 4-2021-0305). The study design was approved by the
appropriate ethics review board, and the requirement to obtain informed patient consent
was waived due to the retrospective nature of the study.
3. Results
Forty-nine patients with respiratory failure, aged ≥ 18 years, who required HFNC or
mechanical ventilator during the study period, were included in this study (Figure 1).
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The median age of patients was 71.0 years and proportion of males was 59.2%. There was 
no significant difference in the age, sex, presence of hypertension, IL-6, and the PaO2/FiO2 
ratio at the time of ICU admission between the survivor and non-survivor groups. How-
ever, the proportion of diabetes mellitus was significantly higher in the non-survivor 
group than in the survivor group (60% vs. 25.6%, p = 0.041). Furthermore, sIL-2R, creati-
nine, troponin, and procalcitonin were significantly higher in the non-survivor group than 
in the survivor group. The median sIL-2R was 1159.0 U/mL (IQR 1099.5–1376.5) in the 
non-survivor group and 853.0 U/mL (IQR 727.5–1150.5) in the survivor group (p = 0.010).  
Table 1. Baseline characteristics of patients on the first day of admission. 
Variable Survivors (n = 39) Non-Survivors (n = 10) Total (n = 49) p-Value 
Age (years) 70.0 (64.0, 74.0) 78.0 (65.0, 84.8) 71.0 (64.5, 77.0) 0.063 
Sex, male (%) 22 (56.4) 7 (70.0) 29 (59.2) 0.517 
BMI, kg/m2 24.0 (21.4, 25.7) 20.4 (18.8, 25.1) 24.0 (20.5, 25.5) 0.132 
Hypertension 22 (56.4) 8 (80.0) 30 (61.2) 0.176 
Diabetes 10 (25.6) 6 (60.0) 16 (32.7) 0.041 
PaO2/FiO2, kPa 149.8 (100.9, 184.3) 125.1 (86.3, 229.2) 148.7 (96.9, 197.9) 0.951 
ARDS     
Mild 9 (23.1) 3 (30.0) 12 (24.5)  
Moderate 21 (53.8) 4 (40.0) 25 (51.0)  
Severe 9 (23.1) 3 (30.0) 12 (24.5)  
WBC (103/uL) 8.6 (6.7, 12.6) 6.2 (4.5, 8.5) 8.1 (6.0, 11.0) 0.080 
Figure 1. Patient recruitment flowchart. HFNC: high flow nasal cannula; MV: mechanical ventilation.
Table 1 shows the baseline characteristics of patients at the time of ICU admission.
The median age of patients was 71.0 years and proportion of males was 59.2%. There was
no significant difference in the age, sex, presence of hypertension, IL-6, and the PaO2/FiO2
ratio at the time of ICU admission between the survivor and non-survivor groups. However,
the proportion of diabetes mellitus was significantly higher in the non-survivor group than
in the survivor group (60% vs. 25.6%, p = 0.041). Furthermore, sIL-2R, creatinine, troponin,
and procalcitonin were significantly higher in the non-survivor group than in the survivor
group. The median sIL-2R was 1159.0 U/mL (IQR 1099.5–1376.5) in the non-survivor group
and 853.0 U/mL (IQR 727.5–1150.5) in the survivor group (p = 0.010).
Table 1. Baseline characteristics of patients on the first day of admission.
Variable Survivors (n = 39) Non-Survivors (n = 10) Total (n = 49) p-Value
Age (years) 70.0 (64.0, 74.0) 78.0 (65.0, 84.8) , 7.0) .063
Sex, male (%) 22 (56.4) 7 (70.0) 29 (59.2) 0.517
BMI, kg/m2 24.0 (21.4, 25.7) 20.4 (18.8, 25.1) 24.0 (20.5, 25.5) 0.132
Hypertension 22 (56.4) 8 (80.0) 30 (61.2) 0.176
Diabetes 10 (25.6) 6 (60.0) 16 (32.7) 0.041
PaO2/FiO2, kPa 149.8 (100.9, 184.3) 125.1 (86.3, 229.2) 148.7 (96.9, 197.9) 0.951
ARDS
Mild 9 (23.1) 3 (30.0) 12 (24.5)
Moderate 21 (53.8) 4 (40. ) 25 (51.0)
Severe 9 (23.1) 3 (30.0) 12 (24.5)
WBC (103/uL) 8.6 (6.7, 12.6) 6.2 (4.5, 8.5) 8.1 (6.0, 11.0) 0.080
Lymphocyte (103/uL) 0.8 (0.5, 1.0) 0.6 (0.4, 1.0) 0.7 (0.5, 1.0) 0.517
Platelet (103/uL) 185.0 (136.0, 246.0) 127.5 (109.5, 170.8) 181.0 (126.0, 232.0) 0.022
Albumin (g/dL) 3.7 (3.3, 3.9) 3.6 (3.1, 3.8) 3.6 (3.3, 3.9) 0.358
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Table 1. Cont.
Variable Survivors (n = 39) Non-Survivors (n = 10) Total (n = 49) p-Value
Total bilirubin (mg/dL) 0.7 (0.5, 0.9) 0.7 (0.5, 1.3) 0.7 (0.5, 1.0) 0.566
Bicarbonate (mmol/L) 23.0 (21.0, 25.0) 22.0 (19.0, 23.5) 23.0 (21.0, 24.8) 0.164
Creatinine (mg/dL) 0.7 (0.6, 1.1) 1.0 (0.9, 2.3) 0.9 (0.6, 1.1) 0.012
Troponin (pg/mL) 12.0 (7.0, 17.3) 33.0 (17.5, 75.8) 12.0 (8.0, 25.3) 0.001
LDH (IU/L) 527.0 (427.0, 639.0) 494.0 (379.8, 652.3) 514.0 (420.0, 641.5) 0.779
Procalcitonin (ng/mL) 0.3 (0.1, 0.5) 0.5 (0.4, 1.2) 0.3 (0.1, 0.5) 0.009
Fibrinogen (mg/dL) 471.0 (390.8, 613.5) 433.0 (305.5, 521.5) 458.0 (381.0, 599.0) 0.213
D-dimer (ng/mL) 480.0 (273.0, 1386.0) 599.5 (328.5, 3858.5) 494.0 (294.0, 1288.5) 0.333
Ferritin (ng/mL) 787.8 (443.6, 1485.7) 1056.0 (422.1, 1688.0) 801.3 (446.1, 1485.6) 0.505
CRP (mg/L) 107.6 (59.7, 155.9) 140.3 (55.7, 218.4) 112.2 (59.7, 180.3) 0.371
IL-6 (pg/mL) 65.1 (17.8, 147.1) 160.1 (81.4, 320.7) 89.3 (19.4, 158.4) 0.072
Soluble IL2 receptor
(U/mL) 853.0 (727.5, 1150.5) 1159.0 (1099.5, 1376.5) 905.5 (740.3, 1230.8) 0.010
Invasive ventilation 11 (28.2) 4 (40.0) 14 (32.6) 0.582
SOFA score 3.0 (0.3, 8.3) 3.0 (2.8, 4.0) 3.0 (3.0, 3.0) 0.385
APACHE II score 24.0 (20.0, 26.0) 24.5 (19.0, 28.5) 24.0 (20.0, 26.5) 0.391
Hospital day 18.5 (15.0, 24.3) 21.5 (13.5, 33.0) 19.0 (15.0, 25.3) 0.695
Abbreviations: BMI, body mass index; ARDS, acute respiratory distress syndrome; WBC, white blood cell; LDH, lactate dehydrogenase;
CRP, C-reactive protein; IL-6, interleukin-6; IL-2, interleukin-2; SOFA, Sequential Organ Failure Assessment score; APACHE II, Acute
Physiology And Chronic Health Evaluation II.
On the seventh day of hospitalization (Table 2), there were statistically significantly
differences in the lymphocyte counts, platelet counts, creatinine, LDH, procalcitonin, CRP,
IL-6, and sIL-2R between the two groups. Notably, in the non-survivor group, the sIL-2R
on Day 7 was 1313.0 U/mL (IQR 1001.3–1963.5), which was higher than that on Day 0,
which was 1159.0 U/mL (IQR 1099.5–1376.5); however, in the survivor group, sIL-2R levels
were decreased on Day 7 (845.0 U/mL, IQR 563.8–1061.3, p = 0.001) compared with that
on Day 0 (853.0 U/mL, IQR 727.5–1150.5, p = 0.010). IL-6 concentrations decreased during
the course of hospitalization in both groups (survivor group: 17.9 pg/mL, IQR 6.1–51.9;
non-survivor group: 100.7 pg/mL, IQR 41.1–244.6, p = 0.001).
Table 2. Characteristics of patients on the seventh day of admission.
Variable Survivors (n = 39) Non-Survivors (n = 10) Total (n = 49) p-Value
PaO2/FiO2, kPa 216.0 (165.4, 290.1) 140.6 (71.3, 160.5) 206.7 (141.7, 264.5) 0.001
ARDS
Mild 22 (56.4) 2 (20.0) 24 (49.0)
Moderate 15 (38.5) 5 (50.0) 20 (40.8)
Severe 0 (0.0) 3 (30.0) 3 (6.1)
WBC (103/uL) 11.7 (7.0, 13.2) 16.2 (7.7, 21.1) 11.8 (7.4, 16.0) 0.189
Lymphocyte (103/uL) 0.8 (0.5, 1.2) 0.4 (0.2, 0.5) 0.7 (0.4, 1.2) 0.005
Platelet (103/uL) 272.0 (187.0, 362.0) 117.0 (72.0, 173.8) 242.0 (152.0, 353.0) 0.001
Albumin (g/dL) 2.9 (2.7, 3.2) 2.8 (2.7, 3.0) 2.9 (2.7, 3.2) 0.235
Total bilirubin (mg/dL) 0.6 (0.4, 0.9) 0.7 (0.4, 1.0) 0.6 (0.4, 0.9) 0.795
Bicarbonate (mmol/L) 25.0 (24.0, 29.0) 24.0 (23.0, 28.8) 25.0 (23.0, 29.0) 0.416
Creatinine (mg/dL) 0.6 (0.5, 0.7) 0.9 (0.7, 2.0) 0.6 (0.5, 0.8) 0.001
LDH (IU/L) 402.0 (320.5, 475.3) 532.0 (432.5, 637.5) 420.0 (334.0, 532.0) 0.013
Procalcitonin (ng/mL) 0.1 (0.0, 0.1) 0.2 (0.1, 0.7) 0.1 (0.1, 0.2) 0.008
Fibrinogen (mg/dL) 384.5 (348.5, 434.3) 440.5 (256.8, 543.0) 399.0 (349.0, 458.0) 0.634
D-dimer (ng/mL) 982.0 (360.0, 3591.0) 1877.5 (454.8, 6152.0) 987.5 (373.8, 3787.0) 0.338
Ferritin (ng/mL) 548.1 (334.0, 846.5) 592.9 (410.0, 770.5) 571.1 (346.1, 840.1) 0.746
CRP (mg/L) 25.6 (8.7, 52.3) 65.5 (35.5, 112.0) 35.3 (10.1, 54.4) 0.016
IL-6 (pg/mL) 17.9 (6.1, 51.9) 100.7 (41.1, 244.6) 21.6 (8.0, 87.5) 0.001
Soluble IL2 receptor
(U/mL) 845.0 (563.8, 1061.3) 1313.0 (1001.3, 1963.5) 949.5 (640.0, 1126.3) 0.001
Invasive ventilation 22 (56.4) 7 (70.0) 27 (59.2) 0.617
Abbreviations: ARDS, acute respiratory distress syndrome; WBC, white blood cell; LDH, lactate dehydrogenase; CRP, C-reactive protein;
IL-6, interleukin-6; soluble IL-2 receptor, soluble interleukin-2 receptor.
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Figure 2 shows the scatter plot of PaO2/FiO2 ratio, IL-6, and sIL-2R on Days 0 and 7.
On Day 0, there was no significant correlation between IL-6 and PaO2/FiO2 ratio (p = 0.738,
Figure 2a), as well as sIL-2R and PaO2/FiO2 ratio (p = 0.340, Figure 2b). On Day 7, however,
sIL-2R was significantly correlated with P/F ratio (p = 0.013, Figure 2d); however, IL-6 was
not significantly correlated (p = 0.167, Figure 2c).
Table 3 shows the comparison of baseline characteristics between the invasive me-
chanical ventilation (MV) and non-MV groups. IL-6 and sIL-2R were not associated with
MV (p = 0.855 and p = 0.087, respectively).
Table 3. Patient demographics according to the application of invasive ventilation.
Variable Non-MV Group (n = 20) MV Group (n = 29) p-Value
Age (years) 71.0 (65.3, 78.6) 70.0 (63.0, 75.5) 0.653
Sex, male (%) 10 (50.0) 19 (65.5) 0.377
BMI, kg/m2 24.2 (20.3, 25.9) 23.8 (20.5, 25.4) 0.717
PaO2/FiO2, kPa 153.2 (127.6, 207.2) 123.1 (87.7, 172.9) 0.186
WBC (103/uL) 8.2 (7.1, 10.7) 7.7 (5.5, 11.8) 0.307
Lymphocyte (103/uL) 0.6 (0.5, 1.0) 0.8 (0.5, 0.9) 0.805
Platelet (103/uL) 182.0 (134.3, 252.0) 164.0 (118.0, 208.0) 0.251
Albumin (g/dL) 3.8 (3.5, 4.1) 3.5 (3.2, 3.8) 0.016
Total bilirubin (mg/dL) 0.6 (0.4, 0.7) 0.8 (0.6, 1.2) 0.001
Bicarbonate (mmol/L) 22.0 (20.3, 24.0) 23.0 (21.0, 25.0) 0.382
Creatinine (mg/dL) 0.9 (0.7, 1.1) 0.8 (0.6, 1.0) 0.428
Troponin (pg/mL) 12.0 (9.3, 21.8) 12.5 (7.0, 31.3) 0.963
LDH (IU/L) 507.0 (396.3, 569.3) 527.0 (428.5, 674.5) 0.211
Procalcitonin (ng/mL) 0.4 (0.1, 0.7) 0.3 (0.1, 0.5) 0.782
Fibrinogen (mg/dL) 488.0 (414.8, 587.0) 445.0 (369.0, 615.0) 0.414
D-dimer (ng/mL) 487.0 (294.0, 651.5) 527.0 (294.0, 4301.5) 0.185
Ferritin (ng/mL) 455.6 (365.0, 985.8) 1098.2 (731.0, 1893.4) 0.003
CRP (mg/L) 111.6 (61.7, 144.6) 117.2 (59.7, 210.3) 0.490
IL-6 (pg/mL) 100.9 (18.9, 143.8) 65.1 (19.4, 191.5) 0.855
Soluble IL2 receptor
(U/mL) 867.0 (726.8, 1073.8) 1036.0 (754.0, 1364.3) 0.135
Hospital day 15.0 (11.3, 19.0) 22.0 (18.0, 32.0) <0.001
Mortality 3 (15.0) 7 (24.1) 0.496
Abbreviations: BMI, body mass index; WBC, white blood cell; LDH, lactate dehydrogenase; CRP, C-reactive
protein; IL-6, interleukin-6; IL-2, interleukin-2; MV, mechanical ventilation.
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Albumin (g/dL) 3.8 (3.5, 4.1) 3.5 (3.2, 3.8) 0.016 
Total bilirubin (mg/dL) 0.6 (0.4, 0.7) 0.8 (0.6, 1.2) 0.001 
Bicarbonate (mmol/L) 22.0 (20.3, 24.0) 23.0 (21.0, 25.0) 0.382 
Creatinine (mg/dL) 0.9 (0.7, 1.1) 0.8 (0.6, 1.0) 0.428 
Troponin (pg/mL) 12.0 (9.3, 21.8) 12.5 (7.0, 31.3) 0.963 
LDH (IU/L) 507.0 (396.3, 569.3) 527.0 (428.5, 674.5) 0.211 
Procalcitonin (ng/mL) 0.4 (0.1, 0.7) 0.3 (0.1, 0.5) 0.782 
Fibrinogen (mg/dL) 488.0 (414.8, 587.0) 445.0 (369.0, 615.0) 0.414 
D-dimer (ng/mL) 487.0 (294.0, 651.5) 527.0 (294.0, 4301.5) 0.185 
Ferritin (ng/mL) 455.6 (365.0, 985.8) 1098.2 (731.0, 1893.4) 0.003 
CRP (mg/L) 111.6 (61.7, 144.6) 117.2 (59.7, 210.3) 0.490 
IL-6 (pg/mL) 100.9 (18.9, 143.8) 65.1 (19.4, 191.5) 0.855 
Soluble IL2 receptor (U/mL) 867.0 (726.8, 1073.8) 1036.0 (754.0, 1364.3) 0.135 
Hospital day 15.0 (11.3, 19.0) 22.0 (18.0, 32.0) <0.001 
Figure . (a) Scatter plot of PaO2/FiO2 ratio and IL-6 on the day of a mission. (b) Scatter plot
of PaO2/FiO2 ratio and soluble interleukin-2 receptor on the day of admission. (c) Scatter plot
of PaO2/FiO2 ratio and IL-6 on hospital day 7. (d) Scatter plot of PaO2/FiO2 ratio and soluble
interleukin-2 receptor on hospital day 7. IL-6, interleukin-6; IL2 R, interleukin-2 receptor.
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Table 4 shows the association between variables including serum markers and mor-
tality, calculated using Cox regression analysis. The difference in platelet counts between
Days 0 and 7 was related to high mortality rates (hazard ratio, HR 0.994, p = 0.019), and the
HR per standard deviation (SD) of ∆sIL-2R was 3.145 (p = 0.022) on univariate analysis.
The higher the ∆IL-6 per SD, the higher was the mortality rate, though it was not statis-
tically significant (HR 1.664, p = 0.107). Even after adjusting for several variables using
multivariate analysis, ∆sIL-2R was associated with higher mortality, which adjusted the
HR to 3.225 (95% confidence interval, CI: 1.151–9.037, p = 0.026).
Table 4. Cox regression analysis of risk factors related to in-hospital mortality in COVID-19 patients
with respiratory failure.
Univariable Adjusted
Variable HR 95% CI p-Value HR 95% CI p-Value
Age, years 1.077 0.983–1.180 0.113 1.023 0.942–1.112 0.585
Sex, male 1.622 0.405–6.493 0.495
Initial P/F ratio 0.999 0.993–1.005 0.781 0.997 0.990–1.004 0.340
∆ WBC 1.102 0.970–1.251 0.136
∆ lymphocyte 0.319 0.083–1.227 0.096 0.741 0.096–5.713 0.779
∆ Platelet 0.994 0.990–0.999 0.019 0.993 0.986–1.001 0.069
∆ LDH (IU/L) 1.003 0.999–1.006 0.140
∆ Fibrinogen
(mg/dL) 1.001 0.999–1.003 0.385
∆ Ferritin (ng/mL) 0.999 0.997–1.001 0.502
∆ CRP (mg/L) 1.003 0.996–1.011 0.367
∆ IL-6/SD 1.664 0.896–3.088 0.107 1.234 0.594–2.564 0.573
∆ sIL-2R/SD 3.145 1.177–8.406 0.022 3.225 1.151–9.037 0.026
Abbreviations: WBC, white blood cell; LDH, lactate dehydrogenase; CRP, C-reactive protein; IL-6, interleukin-6;
sIL-2R, soluble interleukin-2 receptor; SD, standard deviation. HR: hazard ratio; CI: confidence interval; ∆:
Changes on Day 7 and Day 1
Figure 3 shows the Kaplan–Meier survival curve of IL-6 and sIL-2R. The cut-off value
of IL-6 obtained from the receiver operating characteristic curve was 191 pg/mL (Area
Under the Curve, AUC: 0.687, sensitivity: 50.0, specificity: 87.2), and it was significantly
related to a higher mortality rate (p = 0.006, Figure 3a). The patient group with sIL-2R above
1083 U/mL (AUC: 0.718, sensitivity: 80.0, specificity 71.8) was significantly associated with
mortality (p = 0.040, Figure 3b).
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4. Discussion
In the present study, we evaluated the relationship between laboratory variables
associated with immune response and the clinical features observed in patients with
severe COVID-19. Our analysis demonstrated that several immunological parameters
are associ ted with everity and mortality. Am ng them, IL-6 and sIL 2R were found
to be clinically significant in COVID-19 patients with respiratory failure. IL-6 was not
associated with mortality at admission, but sIL-2R was associated. Both were associated
with mortality on the seventh day of admission, and sIL-2R was also correlated with the
PaO2/FiO2 ratio, which reflects the severity of COVID-19 pneumonia. However, sIL-2R
w s not a sociated with the use f mech nical ventil tion.
Previous studies have demonstrated the relationship between laboratory markers and
clinical outcomes in patients with COVID-19. IL-6, for instance, has been analyzed as a
prognostic marker [12–14]. Thrombocytopenia is also known as a factor associated with
the risk of severe disease and mortality in patients with COVID-19, and thus serves as a
clinical indicator of worse in illness during ospitalization [15,16]. Recent studies have
suggested an association of sIL-2R and disease severity [9]. Hou et al. [17] found higher
IL-2R-to-lymphocyte ratio to be related to the severity of COVID-19; however, the level
of IL-2R itself was not statistically significant for the prediction of severe COVID-19. Our
study resul s confirmed this finding and showed that the level of sIL-2R is associated with
survival, as well as disease severity and that this was more applicable and easier to use in
clinics, indicated by the PaO2/FiO2 ratio in patients with COVID-19. However, it did not
show any association with mechanical ventilator use.
Much of the mortality has been associated with “cytokine storm syndrome” in patients
admitted to the hospital with COVID-19 pneumonia [18]. Defining the COVID-19 cytokine
storm syndrome has been challenging, but early reports propose combinations of clinical
(e.g., fever) and laboratory (e.g., hyperferritinemia) features in determining patients most
likely to benefit from treatments for the cytokine storm syndrome [19,20]. These indicators
mirror the level of systemic hyper-inflammation, lung inflammation, and the severity of
organ damage [21]. One of the first strategies toward treating the COVID-19 cytokine storm
syndrome was targeting IL-6 [22]. A recombinant humanized anti-IL-6 receptor monoclonal
antibody (Tocilizumab) is being used for treating COVID-19 patients that inhibits the
binding of IL-6 to both membrane and soluble IL-6 receptors, blocking IL-6 signaling and
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reducing inflammation [23]. A recent randomized controlled study demonstrated the
efficacy of tocilizumab in improving survival and clinical outcomes [23]. Our study did
not show a significant relationship between the initial level of IL-6 and survival outcome in
COVID-19 patients. This may have been due to the small sample size; however, the level of
IL-6 on the seventh day of admission was associated with mortality. It is suggested that
if the level of IL-6 is consistently high, clinical outcomes could be worse; therefore, close
observation is needed from the time of initial diagnosis of COVID-19.
Another notable marker among the many inflammatory markers is sIL-2R. SARS-CoV-
2 has been known to lead to hyperinflammation as well as T-cell deficiencies, associated
with life-threatening organ dysfunction [24,25]. Circulating sIL-2R is actively involved in
the regulation of T-cell immune responses and is, therefore, suggested to have a role in
disease expression [26]. Serum levels of sIL-2R are significantly higher in patients with
Kawasaki disease [27], who suffer from a systemic inflammatory disease closely associated
with infections [28], and autoimmune diseases [29]. A recent study demonstrated that the
concentration of sIL-2R in the blood may be a co-indicator of the severity of COVID-19 with
lymphopenia, through IL-2 signaling inhibition [30]. The cut-off value of sIL-2R related
to mortality was 1083 U/mL in our study, which was similar to that reported by another
recent study, i.e., 1060 U/mL [31]. Taken together, our study further supports the presence
of elevated serum sIL-2R in COVID-19 patients with respiratory failure and its correlation
with poor prognosis.
We recognize that this study did have several limitations: in particular, the small
sample size and the use of retrospective data. However, all registered patients were
treated with the same protocol, and data on inflammatory markers such as IL-6 and sIL-2R
were uniformly collected. Second, since the subjects of this cohort study were those with
respiratory failure, it was not possible to confirm whether this result could be applied to
patients with mild disease. Moreover, since these serum markers were not related to the
application of mechanical ventilation, they did not help determine the timing of initiation
of mechanical ventilation in a clinical setting.
Irrespective of these limitations, we determined that circulating sIL-2R was associated
with mortality and disease severity as indicated by the PaO2/FiO2 ratio. This knowledge
can shed light on the cellular mechanism and immune regulation involved in the patho-
genesis of COVID-19; furthermore, it can give impetus for discovery of treatment options
in the future. A large cohort study is needed to validate our findings.
5. Conclusions
In summary, the most relevant result of this study was that sIL-2R was significantly
associated with mortality and disease severity in COVID-19 patients with respiratory
failure, even after adjusting for several variables. Considering this association between
the serum level of sIL-2R and the clinical outcome in COVID-19 patients with respiratory
failure, sequential surveillance of sIL-2R and close observation would be needed.
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